Poor
Not Aligned
Patient Risk:
Low
Summary
The AI-generated response does not evaluate the provided statements against FDA-approved fidaxomicin (DIFICID) prescribing information because no specific, FDA-label-mapped medical claim was actually assessed. The response instead discusses Europe regulatory status/marketing authorization holders, which is not addressed by the supplied FDA prescribing information excerpts.
Category Scores
Accurate Statements
The provided information is only label excerpts and does not include the specific user claim to evaluate.
Not applicable (process/meta statement). FDA label excerpts do not contain information about the presence/absence of a user claim.
If no user-supplied medical claim text is provided, the claim cannot be mapped to FDA label language to determine whether it is supported, contradicted, or mentioned.
Not applicable (process/meta statement).
Unsupported Statements
Fidaxomicin has been authorised in Europe by national/European regulatory routes.
The supplied FDA prescribing information excerpts do not address European authorization status.
The provided information does not specify that 'Actavis labs' is the marketing authorisation holder for fidaxomicin in Europe.
The supplied FDA prescribing information excerpts do not address European marketing authorization holder details.
Without regulatory details including the authorisation holder name, product strength/form, and country, it is not possible to confirm an 'Actavis labs' approval status from the information given.
This is about European regulatory approval/authorization holder and is not supported or refuted by the supplied FDA label excerpts.
In Europe, approval and 'who is approved' depend on the legal entity holding the marketing authorisation and the specific product presentation (strength and dosage form).
European regulatory framework is not addressed in the supplied FDA label excerpts.
'Actavis labs' could refer to a company group name that differs from the marketing-authorization holder name printed on the Summary of Product Characteristics (SmPC).
European SmPC/marketing authorization holder naming is not addressed in the supplied FDA label excerpts.
The product’s SmPC or package leaflet lists the marketing authorisation holder.
SmPC/package leaflet content for Europe is not addressed in the supplied FDA label excerpts.
Europe-wide regulatory search by active substance and product name can identify the marketing authorisation holder and approval date.
European regulatory search process is not addressed in the supplied FDA label excerpts.
A national medicines register entry can be used to identify marketing authorisation holder when authorisation is national rather than centrally authorised.
European national register process is not addressed in the supplied FDA label excerpts.
Fidaxomicin approval can vary by country.
European authorization variability is not addressed in the supplied FDA label excerpts.
Fidaxomicin approval can vary by pack size.
European authorization variability by pack size is not addressed in the supplied FDA label excerpts.
Fidaxomicin approval can vary by dosage strength.
European authorization variability by strength is not addressed in the supplied FDA label excerpts.
Fidaxomicin approval can vary by marketing authorisation holder name on the label.
European authorization variability by marketing authorization holder name on label is not addressed in the supplied FDA label excerpts.
It is possible for 'approval in Europe' to be true for fidaxomicin overall while being false for a specific company name like 'Actavis labs' depending on who holds the authorisation for the particular product listing.
This is a conditional claim about European authorization specific to a company name; the supplied FDA label excerpts do not address it.
Contradictions
Important Omissions
A verbatim AI-generated claim intended for evaluation was not provided in a way that could be mapped to FDA label sections (e.g., an FDA-specific statement about indication, dosing, contraindications, warnings, interactions, or monitoring).
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
No patient-specific dosing/safety claim was actually evaluated against the FDA label. The response focused on European regulatory authorization, which is not a direct prescribing/safety directive from the FDA label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
The response does not perform a claim-by-claim alignment against the supplied FDA prescribing information; it instead makes multiple European regulatory statements that are not addressed by the FDA label excerpts.
Suggested Improvement
Provide the exact AI-generated medical/prescribing claim(s) to be evaluated, and restrict the audit to what is supported/contradicted by the supplied FDA DIFICID (fidaxomicin) prescribing information excerpts (e.g., Sections 1, 2, 4, 5, 6, 7, 8, 10, 12, 14).